

Peganum harmala enhanced GLP-1 and restored insulin signaling to alleviate AlCl₃-induced Alzheimer-like pathology model

Hanan Salah ,Rofida A Saleh, Tarek F Eissa, Dalaal M Abdallah, Muhammed A Saad

Abstract

Peganum harmala (*P. harmala*) is a folk medicinal herb used in the Sinai Peninsula (Egypt) as a remedy for central disorders. The main constituents, harmine and harmaline, have displayed therapeutic efficacy against Alzheimer's disease (AD); however, the *P. harmala* potential on sensitizing central insulin to combat AD remains to be clarified. An AD-like rat model was induced by aluminum chloride (AlCl₃; 50 mg/kg/day for six consecutive weeks; i.p), whereas a methanolic standardized *P. harmala* seed extract (187.5 mg/kg; p.o) was given to AD rats starting 2 weeks post AlCl₃ exposure. Two additional groups of rats were administered either the vehicle to serve as the normal control or the vehicle + *P. harmala* seed extract to serve as the *P. harmala* control group. *P. harmala* enhanced cognition appraised by Y-maze and Morris water maze tests and improved histopathological structures altered by AlCl₃. Additionally, it heightened the hippocampal contents of glucagon-like peptide (GLP)-1 and insulin, but abated insulin receptor substrate-1 phosphorylation at serine 307 (pS307-IRS-1). Besides, *P. harmala* increased phosphorylated Akt at serine 473 (pS473-Akt) and glucose transporter type (GLUT)4. The extract also curtailed the hippocampal content of beta amyloid (A_β42, glycogen synthase (GSK)-3^β and phosphorylated tau. It also enhanced Nrf2, while reduced lipid peroxides and replenished glutathione. In conclusion, combating insulin resistance by *P. harmala* is a novel machinery in attenuating the insidious progression of AD by enhancing both insulin and GLP-1 trajectories in the hippocampus favoring GLUT4 production.

Scientific Reports 2021, June